Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Journal of Biological Research - Bollettino Della Società Italiana Di Biologia Sperimentale
A small, single-centre molecular profiling study from an underrepresented population reporting mutation frequencies and survival associations, without a comparator arm or randomization, that the authors themselves flag as requiring larger validation.
A two-patient retrospective case series with mixed responses (one PR, one SD) in a heavily pretreated population; descriptive observations that generate hypotheses rather than test them and are explicitly insufficient to demonstrate efficacy or resistance reversal.
A single-center retrospective cohort study with clear findings on EGFR mutation subtypes and TKI sensitivity in a defined population, but limited by retrospective design, lack of survival or clinical outcome detail, and modest sample sizes for the key comparison groups.
Retrospective single-centre cohort with modest follow-up (1.4 years median) and no randomization; observational associations with biomarkers and treatment types are hypothesis-generating rather than definitive.
First-in-human Phase 1 dose escalation with primary focus on safety and tolerability; anti-tumor activity is secondary and minimal (2.5% ORR), consistent with early-phase exploratory work.
A narrative review synthesizing established and emerging biological and targeted therapies across multiple gastrointestinal cancer types, intended to inform clinical decision-making in a rapidly evolving treatment landscape.
A single-center phase 2 trial with a meaningful primary endpoint (40% complete response) and acceptable safety, but limited by lack of control group, modest sample size, and single-center design requiring confirmation in larger studies.